Urokinase Therapy: Dosage Schedules and Coagulant Side Effects

S ummary The effect of a new preparation of urokinase (Roche) has been studied, in the laboratory and in 10 patients and three volunteers. It is a non‐toxic and active fibrinolytic agent if given in adequate dosage, but it was found that a small initial infusion gave rise to a paradoxical coagulant effect in the recipient. This effect was associated with the formation of‘cryofibrinogen’ and an increase in factor‐VIII activity. The coagulant …